Surgical therapy for osteonecotic lesions of the jaws in patients in therapy with bisphosphonates

Journal of Craniofacial Surgery

Volumn 18, Issue 5, 2007, Pages 1012-1017

  Longobardi, Gianluigi ^a,c   Boniello, Roberto ^a   Gasparini, Giulio ^a   Pagano, Immacolata ^b   Pelo, Sandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Italian Agency of Pharmacology   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bisphosphonates; Jaw; Osteonecrosis; Therapy

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLORIDRONIC ACID; NERIDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE NECROSIS; BREAST CANCER; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FACE SURGERY; FEMALE; HUMAN; JAW; KIDNEY CANCER; LUNG CANCER; MALE; MOUTH HYGIENE; MULTIPLE MYELOMA; PAIN; PERFORMANCE; PRIORITY JOURNAL; SYMPTOM; TREATMENT FAILURE;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS;

EID: 34948876879     PISSN: 10492275     EISSN: None     Source Type: Journal    
DOI: 10.1097/scs.0b013e3180f611ef     Document Type: Article

References (21)

1. Ruggiero SL, Mehrota B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117
3. Migliorati CA. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:135
4. Melo D, Obeid G. Osteonecrosis of the Maxilla in a patient with a history of Biphosphonate therapy. J Can Dent Ass 2005;71:111-113
5. Ruggiero S: osteonecrosis of the jaw associated with the use of Biphosphonates. Nassau Dent Soc 2005
6. Ruggiero SL, Gralow J, Hoff AO, et al. "Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patient with cancer". JOPASCO 2006 Jan: vol. 2, issue 1
7. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-1575
8. Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-160
9. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of biphosphonate in breast cancer. J Clin Oncol 2000;18:1378
10. Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology guideline role of biphosphonate in multiple myeloma. J Clin Oncol 2002;20:3719
11. Rodan GA, Fleisch HA. Biphosphonate: mechanisms of action. J Clin Invest 1996;97:2692
12. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract 1999;101:18-26
13. Mashiba T, Nirano T, Turner CH, et al. Suppressed bone turn overby biphosphonates increases micro damage accumulation and reduces some biochemichal properties in dog rib. J Bone Miner Res 2001;5:613
14. Novartis Pharmaceuticals Corporations: Appendix 3 Comprehensive Medical Safety Evalutation Osteonecrosis of the Maxillofacial Area; 2004 Overview
15. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw necrosis in association with cancer chemiotherapy: series of ten cases. J Oral Phatol Med 2005;34:120-123
16. Kapitola J, Zák J, Lacinová Z, et al. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res 2000;49:S101-S106
17. Parfitt AM. The mechanism of coupling: a role for the vasculature. Bone 2000;26:319-323
18. Deckers MM. Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice. J Bone Miner Res 2002;17:998-1007
19. Gerber HP, Vu TH, Ryan AM, et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999;5:623-628
20. Wood JM, Bonjean K. Novel anti-angiogenic effects of the biphosphonate compound zoledronic acid, a potent inhibitor of bone reabsorption. J Pharmacol Exp Ther 2002;302:1055-1061
21. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;2:6538-6544